You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Amoy will develop its AmoyDx Pan Lung Cancer PCR Panel (9-in-1 Plus) as a companion diagnostic test for Haihe's MET kinase inhibitor Glumetinib.
AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.
The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.
AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.
The kit is approved for the qualitative detection of BRCA1 and BRCA2 mutations in patients with different cancer types including breast cancer.